Ridker, P.M., Danielson, E., Fonseca, F.A.H., Genest, J., Gotto Jr., A.M., Kastelein, J.J.P., et al. (2009) Reduction in C-Reactive Protein and LDL Cholesterol and Cardiovascular Event Rates after Initiation of Rosuvastatin: A Prospective Study of the JUPITER Trial. The Lancet, 373, 1175-1182.
http://dx.doi.org/10.1016/S0140-6736(09)60447-5

has been cited by the following article:

• TITLE: A Critical Evaluation of the Role of Routine Uses of Statin as a Tool for Primary Prevention of Cardiovascular Diseases

  AUTHORS: Irtiza Hasan, Tasnuva Rashid, Md. Harun Ur Rashid Bhuiyan

  KEYWORDS: Statin, Cholesterol, Cardiovascular Diseases, Primary Prevention

  JOURNAL NAME: Open Journal of Preventive Medicine, Vol.6 No.4, April 26, 2016

  ABSTRACT: Use of Statin is a cornerstone in modern day medical practice and an essential component for primary prevention of cardiovascular diseases (CVD). Various evidences exemplify and resonate the importance of Statins in reducing CVD mortality and improvement of survivability. However, there is a continental variation in recent guidelines directing lipid-lowering therapy in regards to aim, dose, timing as well as the protocol for initiation of therapy. Similar uncertainties exist with regards to the generalizability of the finding from available evidence, a variation of benefits of Statin with respect to age and gender, the validity of the research conducted and actual gain in survivability and mortality benefits. Thus, there is a need for looking at the actual indications, risk-benefit ratios and cost effectiveness before tediously prescribing Statin for the primary prevention of CVDs. This paper will attempt to critically review the evidence behind the uses of Statins in the primary prevention of CVDs.